TABLE 6.
Results of MTX-IR Monotherapy and Combination Therapy
| Tofacitinib | Adalimumab | Etanercept | Certolizumab | Tocilizumab | |
| MTX-IR Monotherapy | |||||
| 1 year | |||||
| Total cost | $60,607,294 | $74,368,973 | $73,169,567 | $67,909,788 | $66,396,638 |
| Cost PMPM | $5.05 | $6.20 | $6.10 | $5.66 | $5.53 |
| ACR20 responders | 1,055 | 864 | 971 | 855 | 1,059 |
| Cost per ACR20 responder | $57,424 | $86,096 | $75,335 | $79,418 | $62,690 |
| 2 years | |||||
| Total cost | $128,596,040 | $151,904,799 | $151,268,017 | $141,096,133 | $139,014,925 |
| Cost PMPM | $5.36 | $6.33 | $6.30 | $5.88 | $5.79 |
| ACR20 responders | 1,115 | 967 | 1,050 | 960 | 1,118 |
| Cost per ACR20 responder | $115,286 | $157,072 | $144,025 | $146,919 | $124,309 |
| MTX-IR Combination Therapy | |||||
| 1 year | |||||
| Total cost | $63,127,535 | $75,726,239 | $74,467,450 | $68,860,603 | $68,503,703 |
| Cost PMPM | $5.26 | $6.31 | $6.21 | $5.74 | $5.71 |
| ACR20 responders | 900 | 1,004 | 1,069 | 961 | 903 |
| Cost per ACR20 responder | $70,123 | $75,448 | $69,676 | $71,635 | $75,830 |
| 2 years | |||||
| Total cost | $132,687,087 | $155,709,298 | $154,258,796 | $142,891,347 | $141,432,866 |
| Cost PMPM | $5.53 | $6.49 | $6.43 | $5.95 | $5.89 |
| ACR20 responders | 995 | 1,075 | 1,126 | 1,043 | 998 |
| Cost per ACR20 responder | $133,311 | $119,388 | $114,748 | $123,492 | $132,923 |
Note: The analysis for this table is based on 1,321 treated patients. The cost PMPM is based on the total number of 1 million organization (plan) members. ACR = American College of Rheumatology; MTX-IR = methotrexate inadequate responder; PMPM = per member per month.